Search Results 171-180 of 16889 for Amphotericin B
Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma. Rochester, Minn., La Crosse, Wis., Mankato ...
The purpose of this study is to determine the cellular and mechanistic basis of bone marrow hematopoietic dysfunction in untreated Monoclonal B Cell ...
Patients to be included in Cohorts 1 and 4, and who have received rituximab or other B cell ablation therapy within 8 weeks of start of study treatment. 7 ...
Active TB disease happens when the immune system can't control an infection. Germs cause disease throughout the lungs or other parts of the body. Active TB ...
Lee ACH, Edobor A, Lysandrou M, Mirle V, Sadek A, Johnston L, Piech R, Rose R, Hart J, Amundsen B, Jendrisak M, Millis JM, Donington J, Madariaga ML, ...
active Find a doctor whose last name begins with the letter B B · Find a ... Last Name Initial: B. Research. Mayo Clinic researchers are working to improve ...
B · Barrett, Michael T. Ph.D. Barrett.Michael@mayo.edu · Publications · Behfar, Atta M.D., Ph.D. behfar.atta@mayo.edu; Professor of Medicine; Assistant ...
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B · Overview · Participation eligibility · Participating Mayo Clinic ...
1 cells administered following a conditioning lymphodepletion regimen in diffuse large B cell lymphoma (DLBCL) subjects who failed at least two lines of therapy ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.